IRIS - Res&Arch Institutional Research Information System - Research & Archive

GIANNANTONI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.647
EU - Europa 14.649
AS - Asia 9.644
SA - Sud America 1.815
AF - Africa 285
Continente sconosciuto - Info sul continente non disponibili 42
OC - Oceania 16
Totale 42.098
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.308
SG - Singapore 4.476
IT - Italia 2.979
UA - Ucraina 2.965
SE - Svezia 1.954
IE - Irlanda 1.840
RU - Federazione Russa 1.631
BR - Brasile 1.418
CN - Cina 1.244
HK - Hong Kong 1.120
VN - Vietnam 949
DE - Germania 805
FR - Francia 744
FI - Finlandia 651
KR - Corea 566
GB - Regno Unito 410
IN - India 210
CA - Canada 187
TR - Turchia 168
AR - Argentina 131
BD - Bangladesh 129
IQ - Iraq 124
NL - Olanda 108
PK - Pakistan 107
CH - Svizzera 99
BE - Belgio 87
PL - Polonia 87
UZ - Uzbekistan 85
MX - Messico 77
MA - Marocco 68
EC - Ecuador 67
CO - Colombia 65
ID - Indonesia 65
JP - Giappone 63
ZA - Sudafrica 63
AT - Austria 60
SA - Arabia Saudita 59
VE - Venezuela 51
ES - Italia 45
PH - Filippine 41
LB - Libano 37
EU - Europa 36
EG - Egitto 32
RO - Romania 28
MY - Malesia 27
PY - Paraguay 27
CZ - Repubblica Ceca 26
TN - Tunisia 25
GR - Grecia 24
JO - Giordania 24
CL - Cile 23
NP - Nepal 22
CR - Costa Rica 16
ET - Etiopia 16
KE - Kenya 16
LT - Lituania 16
IL - Israele 14
AE - Emirati Arabi Uniti 13
BG - Bulgaria 13
DZ - Algeria 13
AU - Australia 12
IR - Iran 12
UY - Uruguay 12
AZ - Azerbaigian 11
RS - Serbia 11
JM - Giamaica 10
KG - Kirghizistan 10
PE - Perù 10
BO - Bolivia 9
PS - Palestinian Territory 9
AL - Albania 8
PA - Panama 8
PT - Portogallo 8
SK - Slovacchia (Repubblica Slovacca) 8
BB - Barbados 7
KZ - Kazakistan 7
NI - Nicaragua 7
HN - Honduras 6
NO - Norvegia 6
OM - Oman 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
AO - Angola 5
CI - Costa d'Avorio 5
DO - Repubblica Dominicana 5
LU - Lussemburgo 5
MK - Macedonia 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
BH - Bahrain 4
DK - Danimarca 4
EE - Estonia 4
GA - Gabon 4
GE - Georgia 4
HU - Ungheria 4
SY - Repubblica araba siriana 4
AM - Armenia 3
CY - Cipro 3
GH - Ghana 3
HR - Croazia 3
Totale 42.018
Salva come PNG Salva come JPEG
Città #
Singapore 3.054
Chandler 2.472
Dublin 1.838
Jacksonville 1.482
San Mateo 1.228
Hong Kong 1.111
Boardman 826
San Jose 756
Ashburn 680
Santa Clara 575
Seoul 558
Medford 518
Princeton 509
Moscow 495
Dong Ket 467
Lauterbourg 432
Wilmington 402
Andover 322
Ann Arbor 290
Des Moines 263
Altamura 249
Piscataway 243
Beijing 219
Ho Chi Minh City 196
Milan 187
Lawrence 182
Shanghai 157
New York 147
Rome 147
Saint Petersburg 143
Los Angeles 139
Munich 131
Perugia 130
Ottawa 103
Hanoi 99
São Paulo 98
Helsinki 97
The Dalles 91
Norwalk 90
Brussels 86
Turin 84
Izmir 76
Woodbridge 73
Frankfurt am Main 68
Orem 68
Columbus 60
Tokyo 56
Turku 55
Falls Church 53
Baghdad 51
Dallas 47
Redwood City 45
Auburn Hills 44
Chennai 44
Belo Horizonte 43
Houston 41
Chicago 40
Rio de Janeiro 38
Tashkent 38
Warsaw 38
Florence 37
Council Bluffs 36
Bologna 34
Naples 34
Islamabad 31
Stockholm 31
Montreal 29
Ouezzane 28
Atlanta 27
Curitiba 26
Nuremberg 26
San Paolo di Civitate 26
Toronto 26
Brooklyn 25
Denver 25
Dhaka 25
Genoa 25
Redmond 25
Johannesburg 24
Lahore 24
Lausanne 24
Amsterdam 23
Dearborn 23
Istanbul 23
Jeddah 23
Medellín 23
Boston 22
Den Haag 22
Manchester 22
Mondolfo 22
San Francisco 22
Scandiano 22
Guayaquil 21
Napoli 21
Phoenix 21
Bogotá 20
Amman 19
Mumbai 19
Seattle 19
Brasília 18
Totale 23.267
Salva come PNG Salva come JPEG
Nome #
BCG vs Gemcitabina per la terapia endovescicale del carcinoma uroteliale ad alto rischio. Studio prospettico randomizzato. 1.635
1 hour pad test ha un basso valore predittivo nella diagnosi dell’incontinenza urinaria femminile 392
Sacropessia e colposospensione secondo Burch per il trattamento del prolasso genitourinario associato ad incontinenza urinaria: risultati preliminari di uno studio prospettico randomizzato 338
DIAGNOSI ECOGRAFICA DI DEFICIT SFINTERICO URETRALE NELLA DONNA 260
1-hour pad test has low predictive value in the diagnosis of women with urinary incontinence 238
L’infiltrazione intradetrusoriale di tossina botulinica A riduce i livelli tissutali vescicali di nerve growth factor in pazienti affetti da iperattività detrusoriale neurogena. 220
Il Pad test di un’ora nella valutazione dell’incontinenza urinaria femminile 174
Abdominal surgery for uterovaginal prolapse: sacropexy vs hysterocolposacropexy 166
Bacillus Calmette-Guérin versus Gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study 158
Intraprostatic Botox injection in patients with severe benign prostatic hyperplasia. 151
Analisi della funzione vescicale in soggetti con diabete mellito di tipo 1. Risultati preliminari - Atti del Congresso Nazionale SID 149
Stability of Resiniferatoxin stock solutions 148
RUOLO DELLA COLPOSACROPESSIA LAPAROSCOPICA NELLA CORREZIONE DEL PROLASSO UROGENITALE RECIDIVO DOPO FALLIMENTO DI CHIRURGIA TRANVAGINALE CON MESH 145
A personal surgical experience with orthotopic ileal neo-bladder reconstruction: long term functional results 138
Performance of incontinence impact questionnaire (IIQ) in italian population according to educational status 137
The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: a prospective randomized study 136
Abdominal integral pelvic reconstruction plus or minus Burch colposuspension in the treatment of severe uro-genital prolapse associated to urinary incontinence. A RCT with a mid-term follow up 135
IncobotulinumtoxinA in the treatment of neurogenic detrusor overactivity. 135
Body Mass Index e sintomatologia urinaria nella donna 135
Il pad test di un’ora nella valutazione dell’incontinenza urinaria femminile 134
Effects of Botulinum-A toxin intravesical injections on bladder hypersensitive disorders: a pilot study 131
INFILTRAZIONI INTRADETRUSORIALI DI ONABOTULINUMTOXINA IN PAZIENTI AFFETTI DA SINDROME DELLA VESCICA IPERATTIVA: BEST- PRACTICE MANAGEMENT 131
"Advanced analysis in the pressure flow-study: a comparison of methods". 130
Assessment of bladder and urethral sphincter function before and after radical retropubic prostatectomy. 129
Efficacia e tollerabilità della Solifenacina Succinato nella terapia della vescica iperattiva: risultati a breve termine 127
Chirurgia conservativa reiterata nella neoplasia renale plurirecidiva 127
Colposuspension during sacropexy as a prophylaxis for post-operative urinary stress incontinence 126
ONABOTULINUMTOXIN A INTRADETRUSOR INJECTIONS IN THE TREATMENT OF REFRACTORY DETRUSOR OVERACTIVITY DUE TO PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY 125
Bladder and urethral sphincter function after radical prostatectomy: long term follow up. 124
Master di II livello in uroginecologia: quali i risultati chirurgici 124
“Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: Long term follow up”. 124
Efficacy and tolerability of solifenacin 5 mg once daily in the treatment of OAB sindrome 121
A Camey II Modified Neobladder: Long-Term Complications And Functional Results. 121
The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: a psospective randomized study 118
Clinical and surgical predictors of urinary incontinence after radical retropubic prostatectomy. 117
ANALISI DI VARIABILI PSICOLOGICHE IN PAZIENTI CON SINDROME DEL DOLORE PELVICO CRONICO. 117
Il Q-tip test vs ecografia nella diagnosi di ipermobilità uretrale: nostra esperienza 117
Qualità della vita dopo prostatectomia radicale retropubica o radioterapia esterna nel carcinoma prostatico clinicamente localizzato. 116
Intravesical resiniferatoxin versus botulinum A toxin injections for the treatment of neurogenic detrusor overactivity 116
Uterus preservation vs hysterectomy during sacropexy 116
Valsalva Leak Point Pressure measurement: reliability of current procedures in the classification of stress urinary incontinence 114
Utilizzo degli Alfa-litici nelle donne con sintomi del basso tratto urinario 114
Determinazione dei livelli vescicali tissutali di isoprostano 8-epi-PGF2 alfa in pazienti con disfunzioni vescico-sfinteriche ad elevato stress ossidativo 114
"In reply to Dr Silver" 113
Sindrome depressiva e incontinenza urinaria 113
La colposospensione associata a Ricostruzione integrale del pavimento pelvico. 113
Prostasomi e carcinoma prostatico. 112
The potential and promise of using botulinum toxin in the prostate gland. 112
Botulinum A toxin intravesical treatment induces a reduction of nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. 112
Urological dysfunction and upper urinary tract involvement in Multiple Sclerosis patients 111
Botulinum a toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and quality of life 111
Clinical and urodynamic efficacy of Xeomin in the treatment of neurogenic detrusor overactivity: preliminary results. 111
Sacropexy with uterine conservation: results after 5 years 111
"Psychological investigation and sexual dysfunction in spinal cord injury women". 110
Il ruolo del MUCP e del VLPP preoperatori nel predirre i risultati delle pazienti sottoposte a TOT 110
Bladder tissue levels of nerve growth factor in patients with benign prostatic hyperplasia and detrusor overactivity treated with tamsulosin. 110
Sequential Bacillus Calmette Guerin and electromotive mitomycin-C versus Bacillus Calmette Guerin alone for high-risk superficial bladder cancer: a prospective controlled study. 110
Alpha lithic agents for women with lower urinary tract symptoms. 110
Botulinum A toxin modulates afferent fibers in neurogenic detrusor overactivity 110
Correlation between bladder echography and urodynamic examination in patients with multiple sclerosis 109
Botulinum Toxin A Modulates Afferent Fibers in Neurogenic Detrusor Overactivity 109
Prostasomi e carcinoma prostatico. 107
Somministrazione intradetrusoriale di tossina botulinica A in pazienti con iperattività detrusoriale e vescica iperattiva dovute a M. di Parkinson ed Atrofia Multisistemica 107
Autonomic dysreflexia during urodynamics 107
A prospective randomised trial comparing tension-free vaginal tape and transobturator suburethral tape for surgical treatment of stress urinary incontinence 106
Is isoprostane 8-iso-PGF2a a reliable marker of different velico-sphincter dysfunction? 106
Somministrazione intravescicale sequenziale di Bacillus di Calmette-Guerin e Mitomicina C elettrostimolata nei tumori superficiali della vescica ad alto rischio: studio prospettico controllato. 106
Prostasomes and prostate cancer. 106
Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study 106
Association of CYP17,GSTP1, and PON1 Polymorphisms With the Risk of Prostate Cancer 106
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 106
Valsalva leak point pressure and the role of pelvic floor muscles 105
Female sexual dysfunction in urogenital prolapse surgery: colposacropexy vs hysterocolposacropexy 105
PUMA vs Romanzi in the detection of female bladder obstruction and detrusor contractility 105
Bladder and urethral sphincter function after radical retropubic prostectomy: 3 years follow up. 105
Iniezione intravescicale di tossina botulinica A nel trattamento della vescica ipersensibile 105
A Camey II Modified Neobladder: Long-Term Complications And Functional Results. 105
BCG intravescicale versus Mitomicina C per diffusione passiva o elettrostimolata in pazienti con carcinoma in situ della vescica: studio randomizzato. 104
Retropubic versus transobturator mid-urethral slings: in a randomised controlled trial pre-operative VLPP may not predict mid-term outcome 104
Voiding dysfunction in spinal cord lesions of the dorso-lumbar vertebral junction 104
Botulinum-A toxin injections into the detrusor muscle reduce nerve growth factor bladder tissue levels in patients affected by neurogenic detrusor overactivity. 104
Botulinum toxin Type-A activity in prostate cancer 104
OVERACTIVE BLADDER, URINARY INCONTINENCE AND DEPRESSION 104
La colposospensione associata a ricostruzione integrale del pavimento pelvico 103
Urethral retroresistance pressure e Valsalva leak Point Pressure nella valutazione della funzione uretrale in pazienti affette da incontinenza urinaria da sforzo 103
Ruolo della re-turb nei tumori vesciali superficiali ad altro rischio di progressione e recidiva. 102
Studio randomizzato multicentrico TVT vs TOT: esperienza a 2 anni 102
Usefulness of antibiotic prophylaxis in invasive urodynamics in fertile and in postmenopausal female subjects. 102
Bladder and urethral sphincter function after radical retropubic prostatectomy: a 3 year follow up. 102
Intravesical resiniferatoxin versus botulinum-A toxin injections in patients with neurogenic detrusor overactivity: a prospective randomized study 102
BOTULINUM-A TOXIN INJECTIONS INTO THE DETRUSOR MUSCLE REDUCE NERVE GROWTH FACTOR BLADDER TISSUE LEVELS IN P A TIENTS AFFECTED BY NEUROGENIC DETRUSOR OVER- ACTIVITY 102
Bcg vs. Gemcitabina per la terapia endovescicale del carcinoma uroteliale ad alto rischio: Studio prospettico randomizzato 102
Somministrazione intravescicale passiva di tossina botulinica A (BoNT/A) nel trattamento del dolore pelvico cronico: risultati preliminari 101
Bladder tissue levels of NGF in SCI patients with detrusor overactivity before and after botulinum-A toxin injections into the detrusor muscle 101
Bladder dysfunction in Spinal Cord Injury (SCI) vs Multiple Sclerosis (MS): urodynamic findings. 101
SEXUAL DYSFUNCTION IN PATIENTS WITH MULTIPLE SCLEROSIS: PREVALENCE AND IMPACT OF SYMPTOMATIC TREATMENTS 101
Long term follow up of bladder management in spinal cord injury patients: efficacy and tolerability of conventional treatment 100
Botulinum A toxin intradetrusorial injections modulate the bladder expression of NGF, TRKA, P75 and TRPV1 in patients with detrusor overactivity. 100
Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy 100
Urological dysfunction and neurological outcome in survivors from prolonged coma. 99
Totale 13.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 168.859
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 168.859
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.361 0 0 0 0 0 0 0 0 0 213 501 647
2021/20224.752 99 1.023 172 393 181 55 83 1.258 61 55 507 865
2022/20237.476 701 955 233 629 594 901 71 411 2.479 36 347 119
2023/20242.643 217 327 118 53 32 41 438 198 457 73 345 344
2024/20255.708 108 816 171 228 836 167 88 468 1.182 343 797 504
2025/202611.204 936 839 553 1.711 1.314 943 1.894 563 1.363 1.088 0 0
Totale 42.801